文献速递痛风与晶体性关节病

别嘌醇剂量递增对痛风骨侵蚀和尿酸盐体积的影响:随机对照试验中的双能CT成像研究

Effects of Allopurinol Dose Escalation on Bone Erosion and Urate Volume in Gout: A Dual-Energy Computed Tomography Imaging Study Within a Randomized, Controlled Trial.
PubMed 文献 · Arthritis Rheumatol · 2019-08-12

该研究为一项为期2年随机对照试验的影像学子研究,比较立即递增别嘌醇剂量达标与传统剂量治疗1年后再递增对痛风患者骨侵蚀和尿酸盐沉积的影响。结果显示,第2年时对照组CT侵蚀评分进展高于剂量递增组(+7.8% vs +1.4%,P=0.015),且血尿酸达标者DECT尿酸盐体积降低。

要点

  • 立即递增别嘌醇剂量达标可减缓DECT骨侵蚀评分进展。
  • 血尿酸达标与DECT尿酸盐体积降低相关。
  • 传统X线侵蚀或狭窄评分组间无差异。

核心结论

  • 长期降尿酸治疗采用达标策略可影响痛风患者结构损伤并减少尿酸盐晶体沉积。

研究设计与样本

  • 一项为期2年随机对照试验的影像学子研究,纳入正在接受别嘌醇且血尿酸≥0.36 mmol/L的痛风患者,比较立即剂量递增达标与传统剂量治疗1年后递增。
  • 基线、第1年和第2年进行足部DECT扫描及手和足X线检查,DECT评分骨侵蚀和尿酸盐体积。
  • 共87例患者有配对影像数据(剂量递增组42例,对照组45例)。

主要发现

  • 第2年时,对照组CT侵蚀评分进展高于剂量递增组(+7.8% vs +1.4%,P=0.015)。
  • 两组间平片侵蚀或狭窄评分变化无差异。
  • 两组均观察到DECT尿酸盐体积减少;第2年时,对照组中血尿酸<0.36 mmol/L者与剂量递增组DECT尿酸盐体积减少(-27.6%至-28.3%),而对照组中血尿酸≥0.36 mmol/L者未观察到减少(+1.5%)(P=0.023)。

关键数值与推荐

  • 血尿酸目标值为<0.36 mmol/L。
  • DECT骨侵蚀评分变化:对照组+7.8%,剂量递增组+1.4%(P=0.015)。
  • DECT尿酸盐体积变化:达标者及剂量递增组-27.6%至-28.3%,未达标对照组+1.5%(P=0.023)。

临床怎么用

  • 对正在接受别嘌醇且血尿酸≥0.36 mmol/L的痛风患者,可考虑立即递增剂量以达标,可能减缓DECT骨侵蚀进展并减少尿酸盐体积。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine whether allopurinol dose escalation to achieve serum urate (SU) target can influence bone erosion or monosodium urate (MSU) crystal deposition, as measured by dual-energy computed tomography (DECT) in patients with gout. METHODS: We conducted an imaging study of a 2-year randomized clinical trial that compared immediate allopurinol dose escalation to SU target with conventional dosing for 1 year followed by dose escalation to target, in gout patients who were receiving allopurinol and who had an SU level of ≥0.36 mmoles/liter. DECT scans of feet and radiographs of hands and feet were obtained at baseline, year 1, and year 2 visits. DECT scans were scored for bone erosion and urate volume. RESULTS: Paired imaging data were available for 87 patients (42 in the dose-escalation group and 45 in the control group). At year 2, the progression in the CT erosion score was higher in the control group than in the dose-escalation group (+7.8% versus +1.4%; P = 0.015). Changes in plain radiography erosion or narrowing scores did not differ between groups. Reductions in DECT urate volume were observed in both groups. At year 2, patients in the control group who had an SU level of <0.36 mmoles/liter and patients in the dose-escalation group had reduced DECT urate volume (-27.6 to -28.3%), whereas reduction in DECT urate volume was not observed in control group patients with an SU level of ≥0.36 mmoles/liter (+1.5%) (P = 0.023). CONCLUSION: These findings provide evidence that long-term urate-lowering therapy using a treat-to-SU-target strategy can influence structural damage and reduce urate crystal deposition in gout.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Dalbeth N, Billington K, Doyle A, et al. Effects of Allopurinol Dose Escalation on Bone Erosion and Urate Volume in Gout: A Dual-Energy Computed Tomography Imaging Study Within a Randomized, Controlled Trial. Arthritis Rheumatol. 2019. PMID: 31081595. doi:10.1002/art.40929

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。